We argue that evaluation of immune parameters in COVID19 patients need to first be studied to ensure that IL-6 is involved in immunopathology and second to determine at what level or time point in the clinical course of infection, IL-6 produces immunopathology. This evidence concerns the gene IL6 and infection.